Solid Biosciences is monitoring the long-term effects of gene therapy for Duchenne muscular dystrophy, reporting promising data from Phase 1/2 IGNITE-DMD studies. (September 9, 2024)
Source: CGTlive™
Solid Biosciences is monitoring the long-term effects of gene therapy for Duchenne muscular dystrophy, reporting promising data from Phase 1/2 IGNITE-DMD studies. (September 9, 2024)
Source: CGTlive™
Quick Links
Special
© 2024 by NaqsTech Digital | All Rights Reserved | Powered by Medico.